GCCs to Drive Nearly Half of India's Office Leasing by 2026
Source: ET Fintech & Tech
Arth Insight · What this means for your wallet
- Increased demand for office space from GCCs could boost rental yields for commercial properties, potentially increasing returns on real estate investments.
- This trend signals strong economic activity and job creation, which can indirectly benefit your overall financial well-being through a stronger economy.
- While direct investment in commercial real estate is complex, indirect exposure through diversified funds offers a way to participate in this growth.
Wealth-Impact Simulator
See how a change in interest rates hits your loan EMI.
Indicative estimate for education only — not investment advice.
Compare loan ratesGlobal Capability Centres (GCCs) are set to dominate India's office leasing market, potentially accounting for almost half of all space leased by 2026. In the first half of 2026, GCCs leased 16.6 million sq ft of Grade A office space, representing 46% of total leasing across seven major Indian cities.
- ▸GCCs leased 16.6 million sq ft of office space in H1 2026.
- ▸GCCs accounted for 46% of total office leasing in top 7 cities.
- ▸GCCs are projected to drive nearly half of India's office leasing by 2026.
- ▸This trend indicates strong demand for Grade A office spaces.
- ✓GCCs leased 16.6 million sq ft of office space in H1 2026.
- ✓GCCs accounted for 46% of total office leasing in top 7 cities.
- ✓GCCs are projected to drive nearly half of India's office leasing by 2026.
- ✓This trend indicates strong demand for Grade A office spaces.
India's office market is showing remarkable resilience, with Global Capability Centres (GCCs) playing an increasingly significant role in leasing activities. A recent report indicates that GCCs are poised to become the primary drivers of office space demand in the country.
During the first half of 2026, GCCs collectively leased a substantial 16.6 million square feet of Grade A office space. This volume represented a significant 46% of the total office leasing across India's top seven cities, highlighting their growing influence.
The report suggests this trend is likely to continue, with GCCs potentially accounting for nearly half of all office leasing in India by 2026. This sustained demand from GCCs underscores their strategic importance to the Indian commercial real estate sector.
The robust performance of GCCs in leasing office space reflects their continued expansion and investment in India. These centres, often subsidiaries of multinational corporations, provide a range of services including IT, R&D, and business process outsourcing.
The increasing share of GCCs in office leasing signals a positive outlook for the commercial real estate market. It suggests continued job creation and economic activity supported by these global entities. Developers and property managers are likely to see sustained demand for high-quality office spaces, particularly in major metropolitan areas.
This report is for informational purposes only and does not constitute investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What are Global Capability Centres (GCCs)?
GCCs are offshore centres set up by multinational corporations in countries like India to perform various business functions, including IT services, research and development, and business process outsourcing.
Which cities are considered the top seven in India for office leasing?
Typically, the top seven cities include Mumbai, Delhi NCR, Bengaluru, Hyderabad, Pune, Chennai, and Kolkata.
What does 'Grade A' office space refer to?
Grade A office space denotes premium, high-quality buildings in prime locations, offering modern amenities, good infrastructure, and professional management.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Aster DM Healthcare to Invest ₹1,315 Crore to Expand Hospitals in Karnataka
Aster DM Quality Care has announced a massive ₹1,315 crore investment to boost healthcare infrastructure in Karnataka. The funds will be used to build new hospitals and upgrade existing facilities in Bengaluru to provide advanced medical care.
IPOBreakingManipal Health to Invest ₹4,000 Crore for 2,400 New Beds Ahead of IPO
Manipal Health Enterprises plans to invest ₹4,000 crore over the next 3-4 years to add 2,400 hospital beds, increasing its capacity by over 18%. This significant expansion comes just before its anticipated Initial Public Offering (IPO) next week.
BreakingTrump's Proposed 200% Tariff Threatens $9.7 Billion Indian Pharma Exports by 2028
Former US President Donald Trump's proposed 200% tariff on imported generic drugs could put India's significant $9.7 billion generic drug exports to the United States at risk starting 2028. Indian pharmaceutical companies have a two-year window to explore new markets and adapt, while US patients and insurers may face increased healthcare costs.
Related Stories
Aster DM Healthcare to Invest ₹1,315 Crore to Expand Hospitals in Karnataka
Aster DM Quality Care has announced a massive ₹1,315 crore investment to boost healthcare infrastructure in Karnataka. The funds will be used to build new hospitals and upgrade existing facilities in Bengaluru to provide advanced medical care.
IPOBreakingManipal Health to Invest ₹4,000 Crore for 2,400 New Beds Ahead of IPO
Manipal Health Enterprises plans to invest ₹4,000 crore over the next 3-4 years to add 2,400 hospital beds, increasing its capacity by over 18%. This significant expansion comes just before its anticipated Initial Public Offering (IPO) next week.
BreakingTrump's Proposed 200% Tariff Threatens $9.7 Billion Indian Pharma Exports by 2028
Former US President Donald Trump's proposed 200% tariff on imported generic drugs could put India's significant $9.7 billion generic drug exports to the United States at risk starting 2028. Indian pharmaceutical companies have a two-year window to explore new markets and adapt, while US patients and insurers may face increased healthcare costs.
Alembic & NATCO Get USFDA Nod for Cancer Drug; Big Market Opportunity
Indian pharmaceutical firms Alembic Pharmaceuticals and NATCO Pharma have received tentative USFDA approval for a generic version of the cancer drug Olaparib. This approval opens up a significant market opportunity in the US, estimated at ₹11,660 crore, though the commercial launch is contingent on ongoing legal proceedings.